• 1
    Morinaga K, Kishimoto T, Sakatani M, Akira M, Yokoyama K, Sera Y. Asbestos-related lung cancer and mesothelioma in Japan. Ind Health 2001; 39: 6574.
  • 2
    Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: An update. Arch Pathol Lab Med 2005; 129: 140714.
  • 3
    Sterman DH, Albelda SM. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 2005; 10: 26683.
  • 4
    Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: A comparative study. Mod Pathol 2006; 19: 41728.
  • 5
    Yaziji H, Battifora H, Barry TS et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: Identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol 2006; 19: 51423.
  • 6
    Shiomi K, Miyamoto H, Segawa T et al. A novel ELISA system for detection of a ‘N-ERC/Mesothelin’ in the sera of mesothelioma patients. Cancer Sci 2006; 97: 92832.
  • 7
    Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 161216.
  • 8
    Robinson BW, Creaney J, Lake R et al. Soluble mesothelin-related protein: A blood test for mesothelioma. Lung Cancer 2005; 49: S10911.
  • 9
    Yamaguchi N, Hattori K, Oh-eda M, Kojima T, Imai N, Ochi N. A novel cytokine exhibiting megakaryocyte potentiating activity from a human pancreatic tumor cell line HPC-Y5. J Biol Chem 1994; 269: 8058.
  • 10
    Kojima T, Oh-eda M, Hattori K et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995; 270: 21 984–90.
  • 11
    Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA 1996; 93: 13640.
  • 12
    Chang K, Pai LH, Pass H et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992; 16: 25968.
  • 13
    Scholler N, Fu N, Yang Y et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci USA 1999; 96: 11 531–6.
  • 14
    Creaney J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: The potential role of soluble mesothelin-related protein. Hematol Oncol Clin North Am 2005; 19: 102540.
  • 15
    Hino O, Kobayashi E, Nishizawa M et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol 1995; 121: 6025.
  • 16
    Yamashita Y, Yokoyama M, Kobayashi E, Takai S, Hino O. Mapping and determination of the cDNA sequence of the Erc gene preferentially expressed in renal cell carcinoma in the Tsc2 gene mutant (Eker) rat model. Biochem Biophys Res Commun 2000; 275: 13440.
  • 17
    Scherpereel A, Grigoriu B, Conti M et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006; 173: 115560.
  • 18
    Hassan R, Bera T, Pastan I. Mesothelin: A new target for immunotherapy. Clin Cancer Res 2004; 10: 393742.
  • 19
    Onda M, Willingham M, Nagata S et al. New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA. Clin Cancer Res 2005; 11: 584046.
  • 20
    Hassan R, Remaley AT, Sampson ML et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res 2006; 12: 44753.
  • 21
    Hellstrom I, Raycraft J, Kanan S et al. Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 2006; 15: 101420.
  • 22
    Onda M, Nagata S, Ho M et al. Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma. Clin Cancer Res 2006; 12: 422531.
  • 23
    Dogan AU, Baris YI, Emri S, Steele I, Elmishad AG, Carbone M. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res 2006; 66: 50638.
  • 24
    Ramos-Nino ME, Testa JR, Altomare DA et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006; 98: 72334.
  • 25
    Gordon GJ, Rockwell GN, Jensen RV et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005; 166: 182740.
  • 26
    Gordon GJ, Rockwell GN, Godfrey PA et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin Cancer Res 2005; 11: 440614.
  • 27
    Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 2005; 353: 156473.